Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Pharma
FDA speeds Sanofi, Regeneron's application for Dupixent in COPD
The FDA has accepted Sanofi and Regeneron’s application for Dupixent to treat COPD, designating it for priority review with an action date of June 27.
Kevin Dunleavy
Feb 22, 2024 11:25pm
After FDA says no on Dupixent for hives disorder, Japan says yes
Feb 16, 2024 10:54am
Regeneron touts 'favorable' physician reports on Eylea HD
Feb 2, 2024 11:09am
Sanofi, Regeneron score another label expansion for Dupixent
Jan 26, 2024 8:47am
Docs ask pharma for more NSCLC drugs, resources and research
Jan 25, 2024 6:30am
JPM24, Day 1: BMS, Amgen, Regeneron and more
Jan 8, 2024 4:18pm